YD Bio Partner EG Biomed Secures CAP Accreditation for U.S. Laboratory, Strengthening Cancer Diagnostics Capabilities
Key Insights
EG Biomed US Inc. (search), a licensing partner of YD Bio Limited (search), has achieved CAP accreditation for its CLIA-certified laboratory in Bothell, Washington, meeting the gold standard in laboratory quality assurance.
The accreditation strengthens EG BioMed's ability to deliver advanced laboratory-developed tests supporting YD Bio's pancreatic and breast cancer (search) detection programs in the U.S. market.
EG BioMed's Chief R&D Officer presented novel circulating cell-free DNA (search) biomarker findings for monitoring pancreatic cancer (search) metastasis at the AACR conference in Boston.
YD Bio Limited (search), a biotechnology company specializing in DNA methylation-based cancer detection technology, announced that its business partner EG Biomed US Inc. (search) has received accreditation from the College of American Pathologists (search)' (CAP) Laboratory Accreditation Program. The accreditation applies to EG BioMed's CLIA-certified laboratory in Bothell, Washington, which operates under CLIA Certificate #50D2316600.
Laboratory Quality Standards Achievement
CAP accreditation represents the gold standard in laboratory quality assurance, confirming that EG BioMed meets the highest standards of excellence in laboratory operations. Combined with its existing CLIA certification, this recognition enhances EG BioMed's capacity to deliver advanced laboratory-developed tests (LDTs) supporting YD Bio's cancer detection programs and diagnostic innovations in the U.S. market.
"We are thrilled to see our partner company, EG BioMed, achieve this prestigious recognition," said Dr. Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio Limited (search). "CAP accreditation underscores our commitment to improving patient outcomes through scientific innovation and precision, and it strengthens our ability to deliver accurate, reliable diagnostics to patients, and further establishes us as a trusted leader in precision diagnostics."
Strategic Partnership Focus
EG BioMed serves as one of YD Bio's licensing partners for pancreatic and breast cancer (search) detection programs. The partnership also extends to collaboration with 3D Global (search) for developing treatments for eye disorders (search). With CAP accreditation secured, both companies are positioned to expand their diagnostic portfolio, concentrating on early cancer detection and monitoring capabilities.
Scientific Research Developments
EG BioMed's scientific leadership was further demonstrated at the American Association for Cancer Research (search) (AACR) special Conference on Advances in Pancreatic Cancer (search) Research, held in Boston from September 28 to October 1, 2025. Ruo-Kai Lin, Chief R&D Officer of EG BioMed and Professor of Taipei Medical University, presented new findings highlighting a novel circulating cell-free DNA (search) biomarker with potential to monitor metastasis and disease progression in advanced pancreatic cancer.
Company Mission and Future Outlook
Dr. Shen emphasized that this achievement represents an important step toward the company's mission of delivering innovative solutions that enhance quality of life and save lives. YD Bio Limited (search) focuses on advancing clinical trials, new drug development, cancer prevention diagnostics, and stem cell and exosome therapies targeting diseases with high unmet medical need.
The company continues to advance its mission to improve patient outcomes and quality of life through its ophthalmology products and other breakthrough healthcare solutions, while maintaining its role as a recognized supplier of clinical trial drugs and developer of post-market auxiliary products.